Table 1 Clinical-pathological data of the patients involved in this study and their association with overall survival
From: MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas
Parameter | No. of patients in TaqMan analysis | No. of patients in microarray analysis |
|---|---|---|
Histology | ||
ERMS | 66 (41%) | 31 (37%) |
ARMS | 90 (55%) | 53 (63%) |
PAX3-FOXO1 fusion gene-positive | 45 | 30 |
PAX7-FOXO1 fusion gene-positive | 12 | 8 |
Fusion gene-negative | 33 | 15 |
RMS not otherwise specified | 7 (4%) | 0 |
Total | 163 | 84 |
Gender (M/F) | 91/72 | 47/37 |
Median age | 5 (0–23) | 5.5 (0–21) |
Primary tumour location | ||
Favourable | 58 | 32 |
Unfavourable | 79 | 50 |
Unknown | 26 | 2 |
SIOP stage | ||
Stage I | 46 | 25 |
Stage II | 44 | 26 |
Stage III | 21 | 9 |
Stage IV | 43 | 22 |
Unknown | 9 | 2 |
Metastasis | ||
Present at diagnosis | 43 | 22 |
Absent at diagnosis | 108 | 61 |
Unknown | 12 | 1 |
Median survival | ||
Median follow-up time | 4.0 ya | |
Overall survival | 9.6 y | |
N of events (N patients) | 61 (159) | |
Event-free survival | 2.8 y | |
N of events (N patient) | 79 (159) |
